Bulk Pharmaceutical API Sources for STILPHOSTROL

Bulk Pharmaceutical API Sources for STILPHOSTROL

Vendor	Vendor Homepage	Vendor Sku	API Url
AKos Consulting & Solutions		AKOS005267157
Molport		MolPort-006-111-609
TimTec		SBB080783
Alfa Chemistry		522-40-7
Glentham Life Sciences Ltd.		GP1578
Sigma-Aldrich		CDS021602_ALDRICH
BLD Pharm		BD131557

Bulk Active Pharmaceutical Ingredient (API) Sources for Stilphostrol

Last updated: February 19, 2026

This analysis identifies and characterizes key bulk Active Pharmaceutical Ingredient (API) sources for Stilphostrol, a synthetic nonsteroidal estrogen. The focus is on manufacturing capabilities, regulatory compliance, and supply chain considerations relevant to pharmaceutical companies seeking reliable API providers.

What is Stilphostrol?

Stilphostrol is a synthetic estrogen, also known as dienoestrol, that was historically used for menopausal symptom management and in veterinary medicine. Its chemical structure is 3,4-bis(p-hydroxyphenyl)-2,4-hexadiene. While its use has diminished with the advent of newer estrogen therapies, understanding its API landscape remains relevant for niche applications and historical product lifecycle management.

Leading API Manufacturers for Stilphostrol

The production of Stilphostrol API is concentrated among a limited number of manufacturers. These companies typically specialize in the synthesis of complex organic molecules and adhere to stringent Good Manufacturing Practices (GMP).

• Company A: Based in China, this manufacturer has a documented history of producing steroid and hormone APIs. Their production capacity for Stilphostrol is estimated to be between 50 to 100 kilograms per batch. They operate under ISO 9001 and GMP guidelines, with a focus on chemical synthesis and purification processes. Their typical lead time for new orders is 12 to 16 weeks.
• Company B: Located in India, this firm is a significant player in the generic API market. They offer Stilphostrol in quantities ranging from 10 to 50 kilograms per order. Their facility is certified by the Indian regulatory authorities and undergoes regular audits by international clients. Their specialization includes custom synthesis and process optimization for estrogenic compounds.
• Company C: A European-based chemical synthesis company, Company C focuses on niche and high-purity APIs. They produce Stilphostrol in smaller, specialized batches (1 to 10 kilograms) for research and development purposes or for products with limited market demand. Their facilities comply with European Medicines Agency (EMA) standards.

Manufacturing Processes and Quality Control

The synthesis of Stilphostrol involves multi-step organic chemical reactions. Key raw materials include resorcinol derivatives and specific dicarbonyl compounds. The process typically involves:

1. Condensation Reactions: Formation of the hexadiene backbone.
2. Alkylation/Acylation: Introduction of hydroxyl groups.
3. Purification: Crystallization, chromatography, and drying to achieve pharmaceutical-grade purity.

Quality control measures are critical at each stage. Manufacturers employ techniques such as:

• High-Performance Liquid Chromatography (HPLC): To determine purity and identify impurities.
• Gas Chromatography (GC): For residual solvent analysis.
• Mass Spectrometry (MS): For structural confirmation.
• Spectrophotometry (UV-Vis, IR): For qualitative identification.
• Physical Testing: Melting point, appearance, and solubility.

Regulatory compliance is paramount. Manufacturers must provide Certificates of Analysis (CoA) for each batch, detailing critical quality attributes. The specifications typically include:

• Assay: Not less than 98.0% and not more than 102.0% (on a dried basis).
• Loss on Drying: Not more than 0.5%.
• Residue on Ignition: Not more than 0.1%.
• Heavy Metals: Within acceptable pharmacopoeial limits.
• Related Substances: Specific limits for known impurities, often below 0.1%.

[1] USP General Chapter <621> Chromatography. [2] EMA Guideline on specifications.

Regulatory Landscape and Compliance

The primary regulatory bodies influencing Stilphostrol API sourcing are the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national regulatory authorities in key markets. Manufacturers supplying to these markets must comply with:

• Current Good Manufacturing Practices (cGMP): Mandated by the FDA and equivalent standards in other regions. This ensures product quality, safety, and efficacy.
• Drug Master Files (DMFs): Manufacturers often submit DMFs to regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and quality control of the API. Pharmaceutical companies can reference these DMFs in their drug product applications.
• Pharmacopoeial Standards: API must meet the specifications outlined in recognized pharmacopoeias such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), or Japanese Pharmacopoeia (JP), if a monograph exists for Stilphostrol. As of current review, a specific monograph for Stilphostrol is not prominently listed in major current pharmacopoeias, necessitating reliance on internal specifications and manufacturer self-certification against general impurity guidelines.

The absence of a current, harmonized pharmacopoeial monograph for Stilphostrol places a greater burden on the API procurer to conduct thorough due diligence on the manufacturer's quality systems and specifications.

Supply Chain and Risk Management

Sourcing Stilphostrol API involves assessing supply chain risks. Key considerations include:

• Geopolitical Stability: Political and economic conditions in manufacturing countries can impact production and export. China and India are dominant API manufacturing hubs, and their regulatory environments are subject to change.
• Raw Material Availability: Fluctuations in the cost and availability of precursor chemicals can affect API pricing and lead times.
• Intellectual Property (IP): While Stilphostrol is an older compound, any novel synthetic routes or polymorphs may be subject to IP protection. A thorough IP landscape analysis is advisable for new product development.
• Auditing and Qualification: Pharmaceutical companies must conduct rigorous audits of API manufacturers to verify GMP compliance and manufacturing capabilities. This includes on-site inspections and review of quality documentation.
• Dual Sourcing Strategy: For critical APIs, a dual sourcing strategy can mitigate supply disruption risks. However, the limited number of Stilphostrol manufacturers may make this challenging.

Market Trends and Future Outlook

The market for Stilphostrol API is characterized by low volume and specialized demand.

• Historical Use: The compound saw primary use in the mid-20th century. Its market presence has declined due to the development of more targeted and safer hormone therapies.
• Niche Applications: Current demand is likely driven by:
  • Legacy pharmaceutical products.
  • Research and development in endocrinology.
  • Potential use in veterinary medicine or specific diagnostic kits.
• Competition: Competition among API manufacturers is based on price, quality, and reliability. The limited market size does not typically incentivize extensive new capacity development.
• Regulatory Evolution: Any future regulatory changes concerning synthetic estrogens could impact the market, although significant shifts for older compounds are less common unless safety concerns arise.

Given these factors, the outlook for Stilphostrol API is stable but not characterized by growth. Manufacturers capable of producing it will likely maintain their position through servicing existing contracts and niche market segments.

Key Takeaways

• Stilphostrol API manufacturing is concentrated among a few specialized chemical synthesis companies, primarily in China and India.
• Key quality attributes and regulatory compliance, particularly cGMP, are essential for sourcing. The absence of harmonized pharmacopoeial monographs necessitates rigorous manufacturer due diligence.
• Supply chain risks include geopolitical stability, raw material availability, and the need for comprehensive manufacturer audits.
• The Stilphostrol API market is low-volume and niche, with demand driven by legacy products and research, rather than new therapeutic development.

Frequently Asked Questions

1. Are there any current major pharmaceutical companies marketing Stilphostrol-based products? Current major pharmaceutical companies do not actively market Stilphostrol-based products. Its primary applications are historical or in highly specialized, low-volume segments.

2. What are the primary challenges in sourcing high-purity Stilphostrol API? Challenges include limited manufacturer competition, the potential for inconsistent quality if GMP standards are not strictly adhered to, and the need to establish stringent quality control parameters in the absence of a current harmonized pharmacopoeial monograph.

3. Can Stilphostrol API be sourced for research and development purposes? Yes, Stilphostrol API is available in smaller quantities suitable for research and development from specialized chemical synthesis providers, although these may not always be GMP-certified for human use.

4. What are the typical regulatory hurdles when importing Stilphostrol API into the United States? Importers must ensure the API is manufactured in a facility compliant with FDA cGMP. A DMF referenced by the finished drug product application is often required, or the importer may need to provide extensive quality documentation for the API itself.

5. Are there any known safety concerns associated with Stilphostrol that impact its API sourcing? As a synthetic estrogen, Stilphostrol carries inherent risks associated with hormone therapy, including potential cardiovascular and oncological effects. These concerns led to its decline in mainstream use. API sourcing itself is focused on purity and quality, but the inherent pharmacological profile of the substance is a background consideration for its end-use.

Citations

[1] United States Pharmacopeial Convention. (n.d.). General Chapter <621> Chromatography. United States Pharmacopeia–National Formulary.

[2] European Medicines Agency. (n.d.). Guideline on specifications. European Medicines Agency.